Logo
Login
$BLCO
$17.62 +$0.04 (0.23%) Close

Company Executives

$BLCO Management Team

Mr. Andrew Stewart

President - Global Pharmaceuticals and International Consumer

Age 50
Compensation $4.082M USD
Sex Male

Mr. A. Robert Bailey

Executive Vice President

Chief Legal Officer

Age 61
Compensation $5.529M USD
Sex Male

Dr. Yehia Hashad

Executive Vice President - Research & Development

Chief Medical Officer

Age 58
Compensation $4.526M USD
Sex Male

Mr. George Gadkowski

IR Contact Officer

Age -
Compensation -
Sex Male

Mr. Brenton Saunders

Chairman of the Board

Chief Executive Officer

Age 55
Compensation $23.86M USD
Sex Male

Mr. Sam Eldessouky

Chief Financial Officer

Executive Vice President

Age 52
Compensation $6.841M USD
Sex Male

Mr. Luc Bonnefoy

President - Surgical

Age 58
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 10, 2026
Directors
10
serving now
Independent
9 of 10
stated in the proxy
Average tenure
2.9 years
from year joined
CEO also chairs the board
Yes
Brenton L. Saunders
Director Age On board Independent Committees Other public boards 2025 pay Source
Eduardo Alfonso, M.D.
73 2026
0 years
 Independent None stated None stated Not stated
Nathalie Bernier
62 2022
4 years
 Independent
Audit and Risk Committee Science and Technology Committee
None stated $339,988
Steven H. Collis
64 2026
0 years
 Independent None stated Elevance Health Not stated
Sarah B. Kavanagh
69 2022
4 years
 Independent
Audit and Risk Committee Nominating and Corporate Governance Committee
None stated $352,488
Karen L. Ling
62 2024
2 years
 Independent
Talent and Compensation Committee
iRhythm Technologies, Inc. $339,988
John A. Paulson
70 2022
4 years
 Independent
Nominating and Corporate Governance Committee
Acadian Asset Management Inc. $305,605
Russel C. Robertson
78 2022
4 years
 Independent
Audit and Risk Committee Talent and Compensation Committee
None stated $316,843
Thomas W. Ross, Sr.
Lead independent director
 75 2022
4 years
 Independent
Nominating and Corporate Governance Committee Talent and Compensation Committee
None stated $384,988
Brenton L. Saunders
Board chair, CEO
 56 2023
3 years
 Not independent None stated ARS Pharmaceuticals, Inc. Paid as CEO
Andrew C. von Eschenbach, M.D.
84 2022
4 years
 Independent
Nominating and Corporate Governance Committee Science and Technology Committee
None stated $342,488

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

2 disclosed in the proxy filed Apr 10, 2026
BHC
controlling shareholder
$14.7 million
April 2025

Termination of an arrangement under which BHC indemnified the Company for certain indebtedness under the Master Separation Agreement; BHC paid $14.7 million to offset the indebtedness.

With the Company Open in proxy
Icahn Group
Carl C. Icahn and Icahn Group affiliates; Messrs. Icahn and Hu were appointees of the Icahn Group and had been members of the Board since June 2022
Amount not stated
August 2025

Termination of the Director Appointment and Nomination Agreement following the Icahn Group's net long position in BHC shares falling below the required threshold; Messrs. Icahn and Hu resigned from the board effective August 14, 2025.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans